(Q40362170)

19 September 2017

title

Sensitivity of human multiple myelomas and myeloid leukemias to the proteasome inhibitor I. (English)

1 reference

19 September 2017

F Servida

1

1 reference

19 September 2017

D Soligo

2

1 reference

19 September 2017

D Delia

3

1 reference

19 September 2017

C Henderson

4

1 reference

19 September 2017

C Brancolini

5

1 reference

19 September 2017

L Lombardi

6

1 reference

19 September 2017

G Lambertenghi Deliliers

7

1 reference

19 September 2017

language of work or name

1 reference

1 December 2005

1 reference

19 September 2017

1 reference

19 September 2017

volume

19

1 reference

19 September 2017

issue

12

1 reference

19 September 2017

page(s)

2324-2331

1 reference

The proteasome: a suitable antineoplastic target

19 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403987

Catalytic mechanism of the 20S proteasome of Thermoplasma acidophilum revealed by X-ray crystallography

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403987

Proteasome inhibitors induce mitochondria-independent apoptosis in human glioma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403987

Activation of the cell death program by inhibition of proteasome function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403987

Therapeutic anti-cancer targets upstream of the proteasome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403987

The proteasome: a novel target for cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403987

The apoptogenic response of human myeloid leukaemia cell lines and of normal and malignant haematopoietic progenitor cells to the proteasome inhibitor PSI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403987

The proteasome inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403987

Clinical update: proteasome inhibitors in hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403987

The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403987

In vitro and in vivo interaction between cisplatin and topotecan in ovarian carcinoma systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403987

Induction of cell cycle arrest and apoptosis by the proteasome inhibitor PS-341 in Hodgkin disease cell lines is independent of inhibitor of nuclear factor-kappaB mutations or activation of the CD30, CD40, and RANK receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403987

Dephosphorylation targets Bcl-2 for ubiquitin-dependent degradation: a link between the apoptosome and the proteasome pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403987

Anticancer therapy targeting the apoptotic pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403987

Clinical update: proteasome inhibitors in solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403987

Analysis of gene expression in neural cells subject to chronic proteasome inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403987

Programmed cell death and the proteasome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403987

Proteasome inhibitors induced caspase-dependent apoptosis and accumulation of p21WAF1/Cip1 in human immature leukemic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403987

Caspase activation and apoptosis in response to proteasome inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403987

The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403987

Integration of the proteasome inhibitor PS-341 (Velcade) into the therapeutic approach to lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403987

Schedule-dependent molecular effects of the proteasome inhibitor bortezomib and gemcitabine in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403987

Inhibition of the proteasome induces cell cycle arrest and apoptosis in mantle cell lymphoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403987

Dephosphorylation of Bcl-2 by protein phosphatase 2A results in apoptosis resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403987

The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9-negative or Bcl-xL overexpressing cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403987

Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403987

Preferential induction of apoptosis for primary human leukemic stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403987

Differential regulation of noxa in normal melanocytes and melanoma cells by proteasome inhibition: therapeutic implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403987

The role of the ubiquitin-proteasome pathway in apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403987

Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403987

7 January 2021

A combined assay of cell viability and in vitro cytotoxicity with a highly water-soluble tetrazolium salt, neutral red and crystal violet

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403987

7 January 2021

Unregulated proliferation of primitive chronic myeloid leukemia progenitors in the presence of normal marrow adherent cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403987

7 January 2021

Functional characterization of individual human hematopoietic stem cells cultured at limiting dilution on supportive marrow stromal layers

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403987

7 January 2021

Standard-dose therapy for multiple myeloma: The Southwest Oncology Group experience

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403987

7 January 2021

Proteasome inhibitor PS-341 down-regulates prostate-specific antigen (PSA) and induces growth arrest and apoptosis of androgen-dependent human prostate cancer LNCaP cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403987

7 January 2021

Apoptosis induced in L1210 leukaemia cells by an inhibitor of the chymotrypsin-like activity of the proteasome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403987

7 January 2021

Increased IkappaB kinase activity is associated with activated NF-kappaB in acute myeloid blasts

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403987

7 January 2021

Treatment of multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403987

7 January 2021

Identifiers

DOI

10.1038/SJ.LEU.2403987

1 reference

Dimensions Publication ID

19 September 2017

1010016285

0 references

1 reference